Utilization Of Preventive Care Services By Hematopoietic Cell Transplant Survivors  by Lee, S.J. et al.
S226 Poster Session Iundertaken to assess whether the MBNW test can be used as an
early marker of BO in asymptomatic pts.183
LATE ONSET NON-INFECTOUS PULMONARY COMPLICATIONS (LONIPC)
IN ADULT ALLOGENEIC HEMATOPOEITIC CELL TRANSPLANT (HCT) RE-
CIPIENTS
Solh, M., Cao, Q., Majhail, N.S., Weisdorf, D. University of Minnesota,
Minneapolis, MN
LONIPC after allogeneic HCT can contribute to post-transplant
morbidity and mortality and decreased quality of life. We reviewed
data for LONIPC in 451 consecutive adult patients who received
an allogeneic HCT between 2002 and 2007 and survived for $80
days after HCT. Seventy four patients developed LONIPC at a me-
dian of 177 (range, 81-1017) days after HCT; 1-year cumulative in-
cidence of LONIPC was 13% (95% CI, 10%-16%). LONIPC
occurred among 21.3% of myeloablative and 12.6% of non-myeloa-
blative HCT recipients. Graft sources were 49% related donor, 45%
umbilical cord blood and 51% unrelated donor. Acute GVHD had
occurred in 49%. 53% of patients had a prior history of or concom-
itant chronic GVHD. Four groups of LONIPC were observed: dif-
fuse alveolar hemorrhage (DAH, n5 28), idiopathic pneumonia
syndrome (IPS, n5 19), bronchiolitis obliterans (BO, n5 22) and
other (n5 5). A greater proportion of patients with LONIPChad re-
ceived myeloablative conditioning compared to patients who did not
develop LONIPC (57% vs 41%, p5 0.01); the two groups were oth-
erwise comparable. Overall survival at 1-year and 3-years after HCT
was significantly decreased for recipients with LONIPC compared
to those without LONIPC (1 year OS 51% vs. 76%, p\0.01) and
(3 yearsOS 34% vs 57%, p\0.01). 45%of recipients with LONIPC
survived 6 months after developing lung complication. Among pa-
tients with LONIPC, those with DAH and IPS had worse survival
at 1-year after HCT compared to patients with BO (36% vs. 37%
vs. 77%, p\0.01). LONIPC in allogeneic HCT recipients consists
of a heterogeneous group of diseases with varying clinical course and
prognosis. LONIPC is associated with increased mortality among
HCT receipients.Further understanding of the pathogenesis of
each of these entities is still required.184
NEPHROTIC SYNDROME AFTER ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTATION: INCIDENCE AND OUTCOMES
Khaled, Y.A.2, Choi, S.W.1, Hanauer, D.A.3, Levine, J.E.1, Peres, E.1,
Kitko, C.1, Reddy, P.1 1University of Michigan, Ann Arbor, MI; 2Florida
Cancer Institute, Orlando, FL; 3University of Michigan, Ann Arbor, MI
The NIH Consensus recognizes nephrotic syndrome (NS) as part
of the chronic GVHD symptomatology, however the incidence and
outcomes of this manifestation have not been well-defined. To char-
acterize this complication, we conducted an IRB-approved retro-
spective review of 626 consecutive patients (age. 16 yrs: [MRD],
n5 352; [MUD], n5 274) who underwent allogeneic hematopoietic
cell transplantation (HCT) between October 2000 and December
2007 at theUniversity ofMichigan. Conditioning regimens included
full intensity (FIC) in 470 patients and reduced intensity (RIC) in 156
patients. Nephrotic range proteinuria was identified in 17 patients.
Renal biopsy confirmed the diagnosis in seven of these patients.
The median time to onset of NS was 7.3 months following HCT.
Clinical manifestations included hypoalbuminemia (100%), hyper-
cholesterolemia (82%), edema (76%), renal impairment (65%),
and thrombosis (29%). The overall cumulative incidence of NS
was 2.9%: 2.4% in FIC and 4.6% in RIC HCT recipients; and
2.3% inMRD and 3.7%MUDHCT recipients. Of note, in patients
who received irradiation-based conditioning regimens, there was an
increased cumulative incidence of NS compared to those who did
not, 4.8% versus 2.1%, respectively.
Diagnostic symptoms of chronic GVHD based upon the NIH
Consensus was seen in 11 patients (65%). Prior history of acute
GVHD was seen in 11 patients (65%). Interestingly, history of
symptomatic cystitis was seen in 9 patients (53%), eight of whom
had BK virus detected in the urine. All of the patients received sys-
temic steroids (0.25 mg/kg – 2 mg/kg), with or without mycopheno-late mofetil and a calcineurin inhibitor. Additional therapy with
rituximab was administered in nine patients. Durable remission
with no further recurrence of proteinuria was observed in 47% of
the patients (n5 8). The median time to response was 4.8 months.
Recurrence of proteinuria was seen in 29% of the patients (n5 5),
and primary refractory proteinuria was observed in 23% of the pa-
tients (n5 4). Overall survival for the cohort was 49.5% at 4 years
with median follow up of 5.1 years. The median survival from diag-
nosis ofNSwas 2.5 years. As ofMay 2009, eight patients are alive and
nine have died. The causes of death include GVHD (n5 6), relapse
(n5 2) and unknown (n5 1). NS is a rare but important complica-
tion following allogeneicHCT. Early recognition of the clinical pre-
sentations and risk factors may limit the potential morbidity and
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UTILIZATION OF PREVENTIVE CARE SERVICES BY HEMATOPOIETIC CELL
TRANSPLANT SURVIVORS
Lee, S.J., Leisenring, W.M., Khera, N., Chow, E.J., Syrjala, K.L.,
Baker, K.S., Flowers, M.E.D., Martin, P.J. Fred Hutchinson Cancer Re-
search Center, Seattle, WA
Background andMethods: Screening and preventive care guidelines
are available for survivors of autologous and allogeneic hematopoietic
cell transplantation (HCT).We assessed adherence to these guidelines
with a mailed questionnaire sent to all adult survivors in the Fred
Hutchinson Cancer Research Center database, and examined factors
associated with adherence.
Results:Of 3780 survivors after HCT, 1849 (49%) responded. Me-
dian age of respondents at the time of the survey was 55.3 years (18.2-
81.2). 53% were male, 90% White, 68% allogeneic recipients, and
the median time elapsed since transplant was 8.1 years (0.2-38.1).
Younger age, male gender, non-White race, bone marrow trans-
plant, myeloablative conditioning, allogeneic HCT, and HCT in
Poster Session I S227earlier years were more prevalent in non-responders. With adjust-
ments for age and gender recommendations where appropriate, me-
dian adherence to recommended guidelines was 75%. (Table) An
ordinal regression analysis showed that lower adherence was signif-
icantly associated with autologous HCT, concerns about medical
costs, non-White race, male gender, and self-reported lack of knowl-
edge about recommended screening tests, all p\0.01.While 98% of
respondents had medical insurance, 24% reported one or more ac-
tions to limit medical costs: decreasing the dose of prescribed med-
ication, not filling a prescription, not making medical appointments,
not using health services such as physical therapy, or not having a rec-
ommended medical test performed. 3% reported filing for bank-
ruptcy due to medical expenses. Multivariate modeling showed
that concern about costs was associated with female gender, age
younger than 65 years, and low physical and mental functional status
as measured by the SF-12, all p\ 0.01.
Conclusion: Although self-reported adherence to screening prac-
tices overall was high among respondents, selected practices
had\50% adherence, and lower adherence overall was associated
with type of HCT, race, gender, and self-reported financial concerns
and lack of knowledge. 24% of respondents reported that costs influ-
enced their use of medical care. Future work attempting to increase
adherence to recommended preventive care should specifically target
selected practices associated with lower adherence and must recog-
nize that financial concerns may be a significant barrier for some pa-
tients.
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NEUROCOGNITIVE OUTCOMES OF INFANTS WITH ACUTE LYMPHOBLAS-
TIC LEUKEMIA (ALL) UNDERGOING A TOTAL BODY IRRADIATION (TBI)
CONTAINING MYELOABLATIVE HEMATOPOIETIC STEM CELL TRANS-
PLANT (HSCT) BEFORE 18 MONTHS OF AGE
Danner-Koptik, K.1, Golden, S.2, Kletzel, M.1,3, Hijiya, N.1,3,
Dilley, K.1,3 1Children’s Memorial Hospital, Chicago, IL; 2Rosalind
Franklin University, Chicago, IL; 3Northwestern University, Chicago, IL
The objective of this study is to analyze the long term neurocog-
nitive (NC) effects in infants diagnosed with ALL at age less than 12
months and treated with allogeneic HSCT and TBI. Retrospective
review of medical records of eligible patients transplanted from
1992 through 2004 at a single institution was performed. Twenty pa-
tients were identified and we now report on 13 who havemore than 5
year follow-up. Among these 13 patients, 69%were male, 46%Cau-
casian, 38%Hispanic, 15% African American. 38% had central ner-
vous system involvement at diagnosis. 23% had +MLL gene
rearrangement and 8% had t (4:11). The conditioning regimen in-
cluded TBI 1200 cGy (fractions of 150  8), cyclophosphamide
60 mg/Kg daily 3 days and etoposide 1000 mg/m2 single dose (cy-
tarabine was substituted for etoposide in 1 patient). Stem cell sources
are as follows: 54%matched related donor, 8% related matched um-
bilical cord blood (UCB),and 38% unrelatedUCB.Graft versus host
disease (GvHD) prophylaxis were cyclosporine (CsA) alone (n5 3,
23%), CsA+methotrexate (MTX) (n5 7, 54%) or CsA+anti-thymo-
cyte gobulin +MTX. (n5 3, 23%). Leukemia free survival was 85%
at 5 years. Lansky functional scores were100% (n5 7), 90% (n5 2),
70% (n5 1), data in 1 patient not available. NC data was available in
10 patients. Two received formal NC evaluation via Child Psychia-
try, 7 have school individualized educational plans (IEP). Four with
an IEP are inmainstreamed classes while 3 require self-contained/as-
sisted classrooms. Two have no current IEP. 90%have age appropri-
ate social skills; 90% are in organized sports/extra-curricular
activities. 20% are currently in high school, the remainder in ele-
mentary school and advancing. TBI is generally avoided in this pa-
tient population to minimize late effects, and while all patients in
this cohort have some measurable degree of NC effect, their overall
level of function allows for healthy school, family, social, and sport
participation.187
PATIENT CHARACTERISTICS, QUALITY OF LIFE, MOOD STATES, AND
COPING OF OVER 60 COMPARED TO UNDER 60 YEAR OLD AUTOLOGOUS
STEM CELL PATIENTS PRE- AND POST- TRANSPLANT
McLellan, L.1, Dabney, J.1, Rybicki, L.1, Foster, L.W.2, Visnosky, M.1,
Curtis, J.1, Bolwell, B.1 1Cleveland Clinic, OH; 2Cleveland State Univer-
sity, OH
This analysis looks at the differences in experience of transplant of
patients 60+ and under 60 years of age undergoing autologous stem
cell transplantation (ASCT). We reviewed 304 adult patients who
underwent ASCT between June 2003 and December 2007, and
